EARLY ACCESS TO MEDICINES FOR SUFFERERS OF MUSCULAR DYSTROPHY

That this House welcomes the introduction of an early access to medicines scheme to accelerate the pace at which innovative treatments are made available to patients; notes the significant impact such a scheme could have in allowing patients affected by rare diseases access to emerging treatments; further notes that in its September 2013 report on access to high cost drugs for rare diseases the All-Party Parliamentary Group (APPG) for Muscular Dystrophy recommended that the Government bring forward the earlier access to medicines scheme; and praises the work of APPG for Muscular Dystrophy, supported by the Muscular Dystrophy campaigns for its hard work over the last year in pushing for the introduction of this scheme.